Eli Lilly stock: Wells Fargo sets USD 1,330.00 target for Eli Lilly stock

Published on 10/19/2026 at 15:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Eli Lilly reports on October 29, 2026. Eli Lilly stock costs EUR 1,113.20 on October 19, 2026, minus 0.91 percent versus the Xetra close.

Analyst target and earnings date

Wells Fargo set a USD 1,330.00 target for Eli Lilly on October 15, 2026.
Eli Lilly's next earnings call is scheduled for October 29, 2026.
Eli Lilly stock costs EUR 1,113.20 at Lang & Schwarz on October 19, 2026 at 3:07 p.m. CEST, minus 0.91 percent versus the Xetra close of October 16, 2026.
Eli Lilly trades at a price-to-earnings ratio of 42.18.

Aquarellmalerei eines CVD-Deposition-Tools in zarten Blau- und Silbertönen, ein Techniker steht an der Bedienkonsole — Lam Research US5324571083 Deposition Tool als zartes blaues Aquarell mit Techniker im hellen Reinraum, Illustration mit AI erstellt.

Wells Fargo set a USD 1,330.00 price target for Eli Lilly on October 15, 2026, according to Business Insider. Against the USD 1,258.04 market price cited in the same current market context, the target stands 5.72 percent higher. Eli Lilly stock was trading at EUR 1,113.20 at Lang & Schwarz on October 19, 2026 at 3:07 p.m. CEST, minus 0.91 percent versus the Xetra close of October 16, 2026.

October 29 earnings date

Eli Lilly's next earnings call is scheduled for October 29, 2026, at 10:00 a.m. EDT, according to the company's investor-relations calendar at Eli Lilly and Company. The date gives investors the next fixed checkpoint for revenue, earnings and management commentary. The calendar also lists Lilly Innovation Day for December 7, 2026.

EUR 1,113.20 within the range

The Lang & Schwarz price sits EUR 24.60 below the 52-week high of EUR 1,137.80 and EUR 427.70 above the 52-week low of EUR 685.50. That places the quote 2.16 percent below the high and 62.39 percent above the low. The market capitalization is EUR 1,046.4 billion, while the price-to-earnings ratio is 42.18.

Valuation and market comparison

The valuation numbers put the company in a different position from the latest quoted peers. Novo Nordisk traded at USD 38.83, down 0.99 percent, with a price-to-earnings ratio of 9.80 and a market capitalization of USD 172.3 billion on October 16, 2026. Merck traded at USD 145.97, up 0.53 percent, with a price-to-earnings ratio of 116.77 and a market capitalization of USD 360.1 billion on the same date.

Comparison with peers

Eli Lilly and Co.: minus 0.91 percent, P/E 42.18, market capitalization EUR 1,046.4 billion
Novo Nordisk: minus 0.99 percent, P/E 9.80, market capitalization USD 172.3 billion
Merck & Co.: plus 0.53 percent, P/E 116.77, market capitalization USD 360.1 billion

Price stays below the yearly high

The current euro quote remains below its 52-week high, while the next scheduled results date gives the market a defined near-term calendar point. Wells Fargo's USD 1,330.00 target provides a separate valuation reference in the company's home currency.

Eli Lilly stock was trading at EUR 1,113.20 at Lang & Schwarz on October 19, 2026 at 3:07 p.m. CEST, minus 0.91 percent versus the Xetra close of October 16, 2026 at EUR 1,123.40. The further course of trading is shown by the continuously updated real-time quote of Eli Lilly stock.